Phase III Efficacy Still Unproven, Pimavanserin Bags Acadia Deal With Biovail
This article was originally published in The Pink Sheet Daily
Executive Summary
First of two Phase III studies in Parkinson’s disease psychosis is set to yield data in the third quarter.